4basebio UK Societas (4BB) AI Stock Analysis

• Market Cap: £79.75M
• Dividend Yield: N/A
• Average Volume (3M): 999.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: 198.49%
• EPS Growth: -26.66%
• Country: UK
• Employees: 101
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 15,538,518
• 10 Day Avg. Volume: 230
• 30 Day Avg. Volume: 999
• PEG Ratio: -0.25
• Price to Book (P/B): 6.02
• Price to Sales (P/S): 170.11
• P/FCF Ratio: -12.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.97
• Revenue Forecast (FY): £7.00M

• Rating: 41 Neutral
• Price Target: 535.00 p ▼(-13.01% Downside)
• Action: Upgraded Date: 12/07/25
• Date: Action: Upgraded 12/07/25

The overall stock score is primarily impacted by the company's challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. While the CEO's share purchase is a positive sign, it does not significantly offset the financial and technical weaknesses.

Positive Factors

GMP pDNA manufacturing

4basebio provides GMP-grade plasmid DNA, a critical upstream input for gene therapies, cell therapies and vaccines. Owning core manufacturing capability anchors long-term customer relationships, creates high switching costs, and positions the company to capture secular growth in genetic medicine supply chains.

Negative Factors

Persistent losses

Ongoing negative net and EBIT margins indicate the company has not yet converted revenue into sustainable profitability. Over the medium term, continued operating losses erode cash reserves, limit reinvestment ability, and force reliance on external funding unless margins improve through scale or cost control.

4basebio UK Societas Business Overview & Revenue Model

Company Description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzym...

Read more

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzym...

How the Company Makes Money

4basebio generates revenue through multiple streams, primarily by developing and licensing its proprietary gene editing technologies to pharmaceutical and biotechnology companies. The company engages in collaborative research partnerships, which o...

Read more

4basebio generates revenue through multiple streams, primarily by developing and licensing its proprietary gene editing technologies to pharmaceutical and biotechnology companies. The company engages in collaborative research partnerships, which o...

4basebio UK Societas Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.78M	933.00K	506.00K	268.00K	338.00K	462.00K
Gross Profit	100.00K	630.00K	340.00K	239.00K	269.00K	274.00K
EBITDA	-15.18M	-10.97M	-7.34M	-5.41M	-3.21M	-346.00K
Net Income	-14.41M	-12.33M	-7.67M	-5.15M	-3.23M	-719.00K
Balance Sheet
Total Assets	36.87M	44.73M	11.92M	11.69M	14.70M	17.81M
Cash, Cash Equivalents and Short-Term Investments	26.11M	34.60M	3.07M	4.35M	9.59M	15.00M
Total Debt	15.44M	15.22M	10.46M	3.35M	1.76M	1.72M
Total Liabilities	17.89M	18.35M	12.41M	4.57M	3.01M	2.35M
Stockholders Equity	18.98M	26.38M	-492.00K	7.12M	11.70M	15.46M
Cash Flow
Free Cash Flow	-14.04M	-12.31M	-7.67M	-6.64M	-4.25M	-1.87M
Operating Cash Flow	-13.21M	-10.74M	-6.18M	-4.70M	-2.74M	-1.02M
Investing Cash Flow	-1.52M	-1.57M	-1.49M	-1.94M	-1.51M	1.45M
Financing Cash Flow	38.06M	43.87M	6.42M	1.24M	-467.00K	14.43M

4basebio UK Societas Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 615.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:4BB, the sentiment is Neutral. The current price of 615 is above the 20-day moving average (MA) of 504.80, above the 50-day MA of 535.50, and below the 200-day MA of 726.06, indicating a neutral trend. The MACD of -10.57 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 64.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:4BB.

4basebio UK Societas Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£96.66M	6.86	65.83%	8.33%	-3.61%	-6.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£18.13M	-9.67	-210.32%	―	-11.43%	23.40%
AVCT	42 Neutral	£306.18M	-1.74	-361.23%	―	―	―
4BB	41 Neutral	£79.75M	-4.89	-63.53%	―	198.49%	-26.66%
OBD	40 Underperform	£8.15M	-0.25	-316.67%	―	72.17%	79.03%
APTA	40 Underperform	£17.56M	-6.19	-213.66%	―	39.88%	81.33%